{
  "slug": "medication-serious-adverse-event",
  "question": "What are the odds of a serious adverse drug reaction from prescribed medication?",
  "category": "health",
  "no_reliable_estimate": false,
  "perceived": {
    "description": "There is no standing survey that isolates \"fear of a serious adverse drug reaction from a prescribed medication.\" Prescription drug risk sits in a cultural blind spot: patients skim the side-effect leaflet, notice that most entries end in \"rare,\" and file the category under \"things that happen to other people.\" The same readers who will happily interrogate a vaccine's one-in-a-million myocarditis signal tend to accept an SSRI, an NSAID, or a beta-lactam antibiotic with almost no probabilistic framing at all. The gap between that intuition and the aggregate hospitalisation and mortality numbers is one of the larger mismatches on this site.\n",
    "rough_estimate": "most US adults would guess well under 1 in 1,000 for a lifetime fatal ADR",
    "kind": "intuition"
  },
  "native": {
    "display": "~50,000-150,000 fatal adverse drug reactions per year, US (midpoint ~75,000)",
    "numerator": 75000,
    "denominator": 258000000,
    "unit": "per year",
    "population": "US adults, all ages pooled"
  },
  "normalized": {
    "lifetime_us_adult": 0.0171,
    "display": "~1 in 58 lifetime fatal ADR (US adult)",
    "log_value": -1.767,
    "assumptions": "Two different headline numbers live in this entry and it is worth separating them. (1) Lifetime probability of at least one *hospitalisation-level* serious ADR: CDC reports roughly 500,000 ADE-related hospitalisations per year in the US. Against ~258 million US adults that is a per-adult-year hazard of about 1.94 per 1,000. Compounded over 59 years of remaining adult life: 1 − (1 − 0.00194)^59 ≈ 0.108, i.e. roughly 1 in 9 adults experience a serious ADR requiring hospitalisation at some point. (2) Lifetime probability of a *fatal* ADR: Lazarou et al. (JAMA 1998) estimated ~106,000 fatal ADRs in US hospitals in 1994; more recent analyses have argued that figure is on the high end of the plausible envelope, with defensible modern point estimates in the 50,000-150,000/year range. Using a midpoint of ~75,000 fatal ADRs per year against 258 million US adults gives a per-adult-year hazard of ~2.91 × 10^-4 and a compounded lifetime figure of 1 − (1 − 0.000291)^59 ≈ 0.0171, or roughly 1 in 58. The headline normalized value reports the fatal-ADR lifetime number so it can be compared directly with other mortality entries on the site; the hospitalisation-level figure is discussed in the body text.\n",
    "uncertainty": {
      "low": 0.0115,
      "high": 0.034
    },
    "scope": "us_adult_lifetime"
  },
  "sources": [
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/9555760/",
      "title": "Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies",
      "publisher": "JAMA / Lazarou J, Pomeranz BH, Corey PN",
      "source_type": "peer_reviewed",
      "statistic": "Serious ADR incidence 6.7% (95% CI 5.2-8.2%); fatal ADR incidence 0.32% (95% CI 0.23-0.41%); estimated 2,216,000 serious and 106,000 fatal ADRs among US hospitalised patients in 1994",
      "excerpt": "\"The overall incidence of serious ADRs was 6.7% (95% confidence interval [CI], 5.2%-8.2%)\" and \"of fatal ADRs was 0.32% (95% CI, 0.23%-0.41%) of hospitalized patients.\" \"2216000 (1721000-2711000) hospitalized patients had serious ADRs and 106000 (76000-137000) had fatal ADRs.\"\n",
      "source_date": "1998-04-15",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413175711/https://pubmed.ncbi.nlm.nih.gov/9555760/",
      "calculation_notes": "Lazarou et al. pooled 39 prospective studies of hospitalised US patients and reported a 6.7% serious ADR incidence and a 0.32% fatal ADR incidence (per admission, not per patient-year). Extrapolated to 1994 US hospital volumes the authors estimated ~2.2M serious and ~106K fatal ADRs per year, which — if accurate — placed ADRs between the 4th and 6th leading cause of US death at the time. The 106K/year figure anchors the upper end of Likelier's uncertainty band; the per-admission rates are the cleanest cross-study signal and dominate the literature's central tendency.\n",
      "independence_note": "Lazarou is a meta-analysis of 39 earlier prospective studies, so it is not independent of those constituent datasets, but it is the canonical reference point and methodologically independent of both Pirmohamed (UK, prospective admissions cohort) and the CDC ADE surveillance (US emergency department sample).\n"
    },
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/15231615/",
      "title": "Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients",
      "publisher": "BMJ / Pirmohamed M, James S, Meakin S, et al.",
      "source_type": "peer_reviewed",
      "statistic": "6.5% of UK hospital admissions ADR-related; overall fatality 0.15%; ADR directly caused the admission in 80% of cases",
      "excerpt": "\"There were 1225 admissions related to an ADR, giving a prevalence of 6.5%\" and \"The overall fatality was 0.15%.\"\n",
      "source_date": "2004-07-03",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413175749/https://pubmed.ncbi.nlm.nih.gov/15231615/",
      "calculation_notes": "Pirmohamed et al. prospectively analysed 18,820 UK adult hospital admissions and found 6.5% were ADR-related, with a 0.15% fatality rate among those admissions. The result replicates Lazarou's order of magnitude in a completely independent (UK NHS, 2004) dataset and with a cleaner prospective design, which is why it is the preferred independence check in this entry. The lower fatality rate vs. Lazarou reflects both methodology (admission-triggering ADRs vs. in-hospital ADRs) and a more conservative treatment of causality attribution.\n",
      "independence_note": "Fully independent of Lazarou: different country, different decade, different study design (prospective admissions cohort rather than meta-analysis of in-hospital ADRs). This is the strongest cross-check on the hospitalisation-level incidence figure.\n"
    },
    {
      "url": "https://www.cdc.gov/medication-safety/data-research/facts-stats/index.html",
      "title": "FastStats: Medication Safety Data",
      "publisher": "Centers for Disease Control and Prevention (CDC)",
      "source_type": "govt_report",
      "statistic": "~1.5 million US ED visits per year for ADEs; ~500,000 require hospitalisation; >600,000 ED visits per year among adults 65+",
      "excerpt": "\"More than 1.5 million people visit emergency departments for ADEs each year in the United States, and almost 500,000 require hospitalization.\" \"Older adults (65 years or older) visit emergency departments more than 600,000 times each year, more than twice as often as younger people.\"\n",
      "source_date": "2024-01-01",
      "source_accessed": "2026-04-11",
      "archive_url": "http://web.archive.org/web/20260320033225/https://www.cdc.gov/medication-safety/data-research/facts-stats/index.html",
      "calculation_notes": "CDC's ADE surveillance (built on the National Electronic Injury Surveillance System — Cooperative Adverse Drug Event Surveillance project, NEISS-CADES) gives the cleanest contemporary denominator for US serious ADRs: ~1.5M ED visits and ~500K hospitalisations per year. Likelier uses the 500K/year hospitalisation figure as the anchor for the \"serious ADR lifetime risk ≈ 1 in 9\" calculation in the body. The ~600K/year figure for adults 65+ is what drives the \"age 75+ multiplier 5×\" personal factor below.\n",
      "independence_note": "Independent of Lazarou and Pirmohamed: CDC ADE surveillance is a US national ED sample (NEISS-CADES), not a hospitalised-inpatient cohort. It is the only one of the three sources whose numerator directly counts individual ADE events in the general population rather than extrapolating from a study sample.\n"
    },
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/31183532/",
      "title": "Mortality among patients due to adverse drug reactions that occur following hospitalisation: a meta-analysis",
      "publisher": "European Journal of Clinical Pharmacology / Patel PB, Patel TK",
      "source_type": "peer_reviewed",
      "statistic": "Fatal ADR prevalence during hospitalisation: 0.11% (95% CI 0.06-0.18%) from 48 studies; elderly populations 0.27%",
      "excerpt": "\"The pooled prevalence of fatal adverse drug reactions occurring during hospitalisation was 0.11% (95% CI: 0.06-0.18%; I2 = 93%).\"\n",
      "source_date": "2019-09-01",
      "source_accessed": "2026-04-12",
      "archive_url": "https://web.archive.org/web/20260426203728/https://pubmed.ncbi.nlm.nih.gov/31183532/",
      "calculation_notes": "Patel & Patel's 48-study meta-analysis directly updates Lazarou's 0.32% fatal ADR figure with a modern pooled estimate of 0.11%. Extrapolating to ~34M US hospital admissions/year yields ~37,000 fatal ADRs/year — well within this entry's 50,000-150,000 uncertainty band but below Lazarou's 106,000 point estimate, confirming that the 75,000/year midpoint is reasonable. The study also found that elderly populations (0.27%) and ICU/internal-medicine wards (0.46%) drive the overall rate upward.\n",
      "independence_note": "Fully independent of Lazarou (different studies included, different decades, different methodology) and of Pirmohamed (UK prospective vs. global meta-analysis).\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "Death from drug overdose (lifetime, US adult)",
      "lifetime_us_adult": 0.0237
    },
    {
      "label": "Death in a car crash (lifetime, US)",
      "lifetime_us_adult": 0.0108
    },
    {
      "label": "Fatal anaphylaxis, all causes (lifetime, US adult)",
      "lifetime_us_adult": 0.0000363
    },
    {
      "label": "Death in a plane crash (lifetime, US adult)",
      "lifetime_us_adult": 0.000017
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "polypharmacy (5+ concurrent medications)",
      "multiplier": 4,
      "notes": "Drug-drug interactions scale non-linearly with the number of concurrent agents; polypharmacy is the single biggest in-population driver of fatal ADRs and is what pulls the elderly risk curve upward.\n"
    },
    {
      "factor": "age 75+",
      "multiplier": 5,
      "notes": "CDC reports adults 65+ account for >600K of ~1.5M annual ADE ED visits despite being ~17% of the population; the over-75 slice is where the curve turns sharply. Age here is mostly a proxy for polypharmacy, renal clearance, and frailty.\n"
    },
    {
      "factor": "single chronic medication, young otherwise-healthy adult",
      "multiplier": 0.3,
      "notes": "The bottom of the distribution: one well-tolerated agent, normal renal and hepatic function, no interactions. The population-average figure substantially overstates this reader's personal risk.\n"
    },
    {
      "factor": "known drug allergy not flagged in the chart",
      "multiplier": 10,
      "notes": "Missed allergy flags are one of the classic preventable-fatal-ADR pathways and are the biggest single modifiable personal risk factor. Order-of-magnitude estimate.\n"
    }
  ],
  "short_label": "Medication reaction",
  "myth_framing": "underrated",
  "outcome_severity": "serious_harm",
  "exposure_pattern": "recurring",
  "outcome_type": "recoverable_injury",
  "valence": "negative",
  "caveats": "The population-level number here papers over heterogeneity that matters. Age is the dominant axis: adults 65+ account for more than 600,000 of the ~1.5M annual ADE ED visits, so a healthy 30-year-old on a single medication faces a risk well below the headline and an 80-year-old on eight medications faces a risk several multiples above it. Drug class matters almost as much — CDC identifies anticoagulants (~21% of ADE ED visits), diabetes agents including insulin (~14%), and antibiotics (~13%) as the three biggest categories, with opioids and antiplatelets close behind. The Lazarou 106,000 fatal-ADR/year figure has been contested downward in the literature since publication, which is why Likelier's uncertainty band spans roughly 50,000-150,000 US fatal ADRs per year rather than pinning to the 1994 point estimate. Finally this entry covers only adverse reactions to medications taken as prescribed: overdose (accidental or intentional) is tracked under <a href=\"/fears/drug-overdose\">drug-overdose</a>, and drug-induced anaphylaxis — roughly 59% of all fatal anaphylaxis per Jerschow et al. — is the iatrogenic slice of <a href=\"/fears/anaphylaxis-fatal\">anaphylaxis-fatal</a>.\n",
  "quality_score": {
    "d1": 5,
    "d2": 5,
    "d3": 4,
    "d4": 4,
    "d5": 5,
    "d6": 4,
    "d7": 4,
    "d8": 5,
    "avg": 4.5,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-05-25",
    "methodology_version": "1.2"
  },
  "reviewer": "likelier-phase-5-agent",
  "last_reviewed": "2026-04-11",
  "reviewed": true,
  "generated_at": "2026-04-11",
  "image": {
    "alt": "A single white oval pill resting on a pale neutral background, flat vector illustration."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/medication-serious-adverse-event"
}